Can Fite BioPharma Ltd (CANF)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism

Growing momentum for RAS inhibition at ASCO highlights Namodenoson’s RAS pathway inhibition and encouraging...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 3 - Initial statement of beneficial ownership of securities

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness